本帖最后由 老马 于 2013-3-13 13:43 编辑
2 c* T1 Y; k/ e4 U- G0 t; |4 u# r; F3 v
健择（吉西他滨）+顺铂+阿瓦斯汀2 Z! S1 z e4 b
Gemzar +Cisplatin + Avastin, g/ k' q; |! d" f
http://annonc.oxfordjournals.org/content/21/9/1804.full% |1 t* I) T, z0 ]7 ~
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ( B% c" k9 e8 B
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
3 ~& L- v3 ?" R7 ?' AResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. # B: X% u0 l/ E. z2 K! G9 |$ K) E
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 760)
r- R' p! h6 C6 U( G华为网盘附件：4 [% d% f0 l) J+ m" c: f
【华为网盘】ava.JPG
7 f+ W' Q1 ]. z# D |
显身卡
